

29 October 2010

AquaBounty Technologies, Inc.
(“AquaBounty” or “the Company”)

Result of General Meeting

Further to the announcement of 5 October 2010, the Board of AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, announces that at the General Meeting of shareholders held earlier today, all resolutions were duly passed.

The Company will now proceed to raise approximately £3.18 million (c.\$5.0 million) before expenses by means of a subscription of new Common Shares (the “Subscription Shares”) by Linnaeus Capital Partners B.V. (“Linnaeus”). Admission to AIM and commencement of trading of the Subscription Shares is scheduled to occur on 2 November 2010. The Company expects that this funding will enable AquaBounty to continue its activities for at least the next 12 months.

Richard Clothier, Chairman of AquaBounty, commented: “We are very pleased that shareholders have endorsed the strong support of Linnaeus; we welcome Anita Hamilton onto the Board and look forward to benefiting from her expertise and experience in the sector. The Board remains hopeful that the Company will receive approval for AquAdvantage® Salmon from the U.S. Food and Drug Administration, and that we will soon be in a position to move into the commercial phase of development of this unique product.”

For further information, please contact:

AquaBounty Technologies
David Frank, Chief Financial Officer

+1 781 899 7755

Nomura Code Securities
Richard Potts, Giles Balleny

+44(0)20 7776 1200

Corfin Public Relations
Harry Chathli, Claire Norbury

+44(0)20 7596 2860